[1\/3] A vial labelled \"CureVac COVID-19 Vaccine\" is seen in this illustration taken January 16, 2022. REUTERS\/Dado Ruvic\/Illustration<\/p>\n
May 19 (Reuters) - CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc (PFE.N) and BioNTech over the use of mRNA technology and that a U.S. court had granted its request to transfer the trial.<\/p>\n
The company said it filed a counterclaim alleging that Pfizer and its German partner BioNTech infringed on nine of its patents, broader than its original claim of three patents.<\/p>\n
In July 2022, CureVac had filed a patent lawsuit against BioNTech over the use of mRNA technology in the companies' COVID-19 vaccine.<\/p>\n
The transfer of the trial to the Eastern District of Virginia from the Federal District Court of Massachusetts is expected to accelerate progress of the case and allow for a likely 2024 trial date, CureVac said on Friday.<\/p>\n
Pfizer and BioNTech did not immediately respond to requests for comment.<\/p>\n
Pfizer and BioNTech in response had filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by CureVac.<\/p>\n
The companies have previously told the court that their COVID vaccine Comirnaty does not work in the same way as CureVac's patented technology.<\/p>\n
Pfizer and BioNTech are also facing patent infringement lawsuits from other companies.<\/p>\n
Reporting by Raghav Mahobe in Bengaluru<\/p>\n
Our Standards: The Thomson Reuters Trust Principles.<\/p>\n
<\/p>\n
See more here: <\/p>\n
CureVac files expanded patent lawsuit against Pfizer\/BioNTech over ... - Reuters<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" [1\/3] A vial labelled \"CureVac COVID-19 Vaccine\" is seen in this illustration taken January 16, 2022. Continue reading